Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 216 participants.

Also called NCT06262685

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 216 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06262685
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06262685. Randomized; single masking; primary purpose treatment. Start 2024-03-04 (anticipated); primary completion 2025-02-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins
Acronym
PREVESTATGx
Condition
Cardiovascular Diseases
Condition
Dyslipidemias
Condition
Statin Adverse Reaction
Condition
Pharmacogenic Myopathy
Intervention (Other)
Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines
Intervention (Other)
Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines
Intervention (Other)
Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines
Intervention (Other)
Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines
Intervention (Other)
Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines
Intervention (Other)
Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines
Intervention (Other)
Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines
Intervention (Other)
Standard of Care (SoC) dosing of atorvastatin
Intervention (Other)
Standard of Care (SoC) dosing of simvastatin
Intervention (Other)
Standard of Care (SoC) dosing of pitavastatin
Intervention (Other)
Standard of Care (SoC) dosing of rosuvastatin
Intervention (Other)
Standard of Care (SoC) dosing of prasavastatin
Intervention (Other)
Standard of Care (SoC) dosing of lovastatin
Intervention (Other)
Standard of Care (SoC) dosing of fluvastatin
Lead sponsor
Instituto de Investigación Hospital Universitario La Paz (class: other)
Collaborator
Instituto de Salud Carlos III (class: other government)

Record details

Record id
cardio:ct-nct06262685
Content hash
bfed0fb2a371a4f6929a9d056d93d77371c3970efb543e43982b9e80c6495c04